这是一篇来自已证抗体库的有关人类 ER的综述,是根据170篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合ER 抗体。
ER 同义词: ESR; ESRA; ESTRR; Era; NR3A1; estrogen receptor; ER-alpha; estradiol receptor; estrogen nuclear receptor alpha; estrogen receptor alpha E1-E2-1-2; estrogen receptor alpha E1-N2-E2-1-2; nuclear receptor subfamily 3 group A member 1

基因敲除验证
赛默飞世尔小鼠 单克隆(AER314)
  • 免疫印迹 (基因敲除); 人类; 图4
赛默飞世尔 ER抗体(Neomarkers, AER314)被用于免疫印迹 (基因敲除)在人类样品上 (图4). Clin Cancer Res (1996) ncbi
圣克鲁斯生物技术小鼠 单克隆(F-10)
  • 免疫印迹 (基因敲除); 人类; 图1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹 (基因敲除)在人类样品上 (图1). PLoS ONE (2016) ncbi
赛默飞世尔
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图2
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S)被用于免疫印迹在人类样品上 (图2). J Cancer (2016) ncbi
小鼠 单克隆(1D5)
  • 免疫组化; 人类; 1:300; 图2
赛默飞世尔 ER抗体(Thermo, 1D5)被用于免疫组化在人类样品上浓度为1:300 (图2). Diagn Pathol (2016) ncbi
小鼠 单克隆(33)
  • 细胞化学; 小鼠; 1:50; 图5
赛默飞世尔 ER抗体(Thermo Scientific, MA1-310)被用于免疫细胞化学在小鼠样品上浓度为1:50 (图5). Mol Cell Endocrinol (2016) ncbi
小鼠 单克隆(33)
  • FC; 人类; 1:20
赛默飞世尔 ER抗体(Thermo, MA1310)被用于流式细胞仪在人类样品上浓度为1:20. Nat Commun (2016) ncbi
小鼠 单克隆(TE111.5D11)
  • ChIP-Seq; 人类; 图5a
赛默飞世尔 ER抗体(Thermo Scientific, MA5-13065)被用于ChIP-Seq在人类样品上 (图5a). Mol Oncol (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:50; 图s2
赛默飞世尔 ER抗体(Thermo Sc. Labvision, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图s2). J Exp Clin Cancer Res (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:200; 表1
赛默飞世尔 ER抗体(ThermoFisher Scientific, MA1-39540)被用于免疫组化-石蜡切片在人类样品上浓度为1:200 (表1). Oncol Lett (2016) ncbi
小鼠 单克隆(33)
  • 免疫印迹; 猪; 图3
赛默飞世尔 ER抗体(Pierce, MA1-310)被用于免疫印迹在猪样品上 (图3). J Biol Chem (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100; 图s1
赛默飞世尔 ER抗体(Neomarkers, RM-9101-S1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图s1). BMC Cancer (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Ann Surg Oncol (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100; 表1
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (表1). Pathol Oncol Res (2016) ncbi
兔 单克隆(Sp1)
  • 细胞化学; 人类; 1:10; 图s13b
赛默飞世尔 ER抗体(Labvision, RM-9101-S)被用于免疫细胞化学在人类样品上浓度为1:10 (图s13b). Nat Commun (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • 免疫组化-P; 鸡; 4 ug/ml; 图3
赛默飞世尔 ER抗体(NeoMarkers, TE111.5D11)被用于免疫组化-石蜡切片在鸡样品上浓度为4 ug/ml (图3). Acta Histochem (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类
赛默飞世尔 ER抗体(Thermo Fisher, RM-9101-S)被用于免疫组化-石蜡切片在人类样品上. Ann Oncol (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100; 图2
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S)被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图2). PLoS ONE (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化-石蜡切片在人类样品上. Oncotarget (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • ChIP; 小鼠; 图1h
  • 免疫印迹; 小鼠; 图1d
赛默飞世尔 ER抗体(Thermo Scientific, TE111.5D11)被用于染色质免疫沉淀 在小鼠样品上 (图1h) 和 免疫印迹在小鼠样品上 (图1d). J Clin Invest (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • ChIP; 小鼠; 图1h
  • 免疫印迹; 小鼠; 图1d
赛默飞世尔 ER抗体(Thermo Scientific, TE111.5D11)被用于染色质免疫沉淀 在小鼠样品上 (图1h) 和 免疫印迹在小鼠样品上 (图1d). Oncogene (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:100
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S1)被用于免疫组化在人类样品上浓度为1:100. Pathol Res Pract (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:60
赛默飞世尔 ER抗体(Thermo Fisher Scientific, RM9101S)被用于免疫组化-石蜡切片在人类样品上浓度为1:60. Clin Cancer Res (2015) ncbi
小鼠 单克隆(6F11)
  • 免疫组化; 猪; 图s5
赛默飞世尔 ER抗体(ThermoFisher Scientific, 6F11)被用于免疫组化在猪样品上 (图s5). BMC Cancer (2015) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图2
赛默飞世尔 ER抗体(Thermo Scientific, RM9101S0)被用于免疫印迹在人类样品上 (图2). Cell Death Dis (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:500
赛默飞世尔 ER抗体(NeoMarkers, RM9101)被用于免疫组化在人类样品上浓度为1:500. Mol Clin Oncol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:50; 表2
赛默飞世尔 ER抗体(Thermo Lab Vision, RM-9101-S)被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (表2). Breast Cancer Res Treat (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:50
赛默飞世尔 ER抗体(Thermo Scientific Lab Vision, RM-9101-S)被用于免疫组化-石蜡切片在人类样品上浓度为1:50. Breast Cancer Res Treat (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:500
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化在人类样品上浓度为1:500. Breast (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类
赛默飞世尔 ER抗体(Thermo Scientific Lab Vision, SP1)被用于免疫组化-石蜡切片在人类样品上. Niger J Clin Pract (2015) ncbi
兔 单克隆(Sp1)
  • 细胞化学; 人类; 1:50
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S1)被用于免疫细胞化学在人类样品上浓度为1:50. J Transl Med (2015) ncbi
小鼠 单克隆(33)
  • 免疫印迹; 人类
赛默飞世尔 ER抗体(Thermo Scientific, MA1-310)被用于免疫印迹在人类样品上. BMC Cancer (2015) ncbi
小鼠 单克隆(EVG F9)
  • 免疫组化; 兔
赛默飞世尔 ER抗体(Thermo Scientific, MA3-310)被用于免疫组化在兔样品上. Cell Biochem Funct (2015) ncbi
小鼠 单克隆(6F11)
  • 细胞化学; 大鼠
赛默飞世尔 ER抗体(Thermo Scientific, 6F11)被用于免疫细胞化学在大鼠样品上. Exp Oncol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:80
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化在人类样品上浓度为1:80. Gynecol Oncol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100
赛默飞世尔 ER抗体(LabVision, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Cancer Res Treat (2016) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类
赛默飞世尔 ER抗体(Lab Vision, SP1)被用于免疫组化-石蜡切片在人类样品上. Pathol Oncol Res (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100; 表4
赛默飞世尔 ER抗体(Thermo Scientific, RM-9101-S)被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (表4). PLoS ONE (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 表3
赛默飞世尔 ER抗体(NeoMarkers, RM-9101-S1)被用于免疫组化-石蜡切片在人类样品上 (表3). PLoS ONE (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:50
赛默飞世尔 ER抗体(Neomarker, RM-9101-R7)被用于免疫组化在人类样品上浓度为1:50. Breast Cancer Res Treat (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:80
赛默飞世尔 ER抗体(Thermo Fisher Scientific, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:80. Int J Gynecol Pathol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:400
赛默飞世尔 ER抗体(Thermo, SP1)被用于免疫组化在人类样品上浓度为1:400. Balkan Med J (2014) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图3
赛默飞世尔 ER抗体(Neomarkers, RM-9101)被用于免疫印迹在人类样品上 (图3). Int J Oncol (2015) ncbi
小鼠 单克隆(TE111.5D11)
  • ChIP; 人类
赛默飞世尔 ER抗体(Thermo, MA5?C13062)被用于染色质免疫沉淀 在人类样品上. Cell Death Differ (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:200
赛默飞世尔 ER抗体(Zymed, SP1)被用于免疫组化在人类样品上浓度为1:200. Breast Cancer Res Treat (2015) ncbi
小鼠 单克隆(6F11)
  • 免疫组化; 人类
  • 免疫组化; 大鼠
赛默飞世尔 ER抗体(Thermo Scientific, 6F11)被用于免疫组化在人类样品上 和 在大鼠样品上. Exp Oncol (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:50
赛默飞世尔 ER抗体(Thermo Fisher Scientific, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:50. Oncotarget (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:500
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化在人类样品上浓度为1:500. BMC Womens Health (2014) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:3000
赛默飞世尔 ER抗体(生活技术, 49-1002)被用于免疫组化在人类样品上浓度为1:3000. Dev Neurobiol (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100
赛默飞世尔 ER抗体(Thermo Scientific, SP-1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Am J Clin Pathol (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100; 图2
赛默飞世尔 ER抗体(NeoMarkers, RM-9101-SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图2). PLoS ONE (2014) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类
赛默飞世尔 ER抗体(Thermo, SP1)被用于免疫印迹在人类样品上. Oncotarget (2014) ncbi
小鼠 单克隆(33)
  • 细胞化学; 人类; 1:200
  • 免疫印迹; 小鼠; 1:200
赛默飞世尔 ER抗体(Thermo, MA1-310)被用于免疫细胞化学在人类样品上浓度为1:200 和 免疫印迹在小鼠样品上浓度为1:200. Nat Med (2014) ncbi
小鼠 单克隆(TE111.5D11)
  • 免疫沉淀; 人类; 1:200
赛默飞世尔 ER抗体(Thermo, MA5-13065)被用于免疫沉淀在人类样品上浓度为1:200. Nat Med (2014) ncbi
小鼠 单克隆(TE111.5D11)
  • ChIP; 猪
  • 免疫印迹; 猪; 1:500
赛默飞世尔 ER抗体(Thermo, MA5-13065)被用于染色质免疫沉淀 在猪样品上 和 免疫印迹在猪样品上浓度为1:500. J Steroid Biochem Mol Biol (2014) ncbi
小鼠 单克隆(H4624)
  • FC; 羊; 1:10
  • 免疫组化; 羊; 1:50
赛默飞世尔 ER抗体(Invitrogen, 41700)被用于流式细胞仪在羊样品上浓度为1:10 和 免疫组化在羊样品上浓度为1:50. Microsc Res Tech (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:80
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化在人类样品上浓度为1:80. Virchows Arch (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:500
赛默飞世尔 ER抗体(LabVision, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:500. Br J Cancer (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类
赛默飞世尔 ER抗体(Thermo, SP1)被用于免疫组化-石蜡切片在人类样品上. Lab Invest (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:200
赛默飞世尔 ER抗体(Lab Vision, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:200. APMIS (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100
赛默飞世尔 ER抗体(Labvision, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100. Mod Pathol (2014) ncbi
小鼠 单克隆(AER314)
  • 免疫印迹 (基因敲减); 人类; 图s8
赛默飞世尔 ER抗体(Thermo Fisher, AER314)被用于免疫印迹 (基因敲减)在人类样品上 (图s8). Nat Commun (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类
赛默飞世尔 ER抗体(Thermo Scientific, SP-1)被用于免疫组化在人类样品上. Head Neck (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:60
赛默飞世尔 ER抗体(Thermo Fisher, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:60. Int J Cancer (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:200; 图2
赛默飞世尔 ER抗体(Zymed, clone SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:200 (图2). Int J Clin Exp Pathol (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类
赛默飞世尔 ER抗体(Neomarkers, SP1)被用于免疫组化-石蜡切片在人类样品上. J BUON (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:500; 表1
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:500 (表1). Clinics (Sao Paulo) (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类
赛默飞世尔 ER抗体(Zymed, SP1)被用于免疫组化在人类样品上. Cancer Biol Med (2012) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:50; 图1
赛默飞世尔 ER抗体(Neomarkers, RM-9101-S1)被用于免疫组化在人类样品上浓度为1:50 (图1). Br J Cancer (2013) ncbi
小鼠 单克隆(1D5)
  • 免疫组化; 人类; 表1
赛默飞世尔 ER抗体(Zymed, 1D5)被用于免疫组化在人类样品上 (表1). Int J Surg Pathol (2014) ncbi
小鼠 单克隆
  • 免疫组化-P; 人类
赛默飞世尔 ER抗体(Zymed Laboratories, 491002)被用于免疫组化-石蜡切片在人类样品上. PLoS ONE (2013) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-P; 人类; 1:100; 图1
赛默飞世尔 ER抗体(Neomarkers, 6F11)被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图1). Oncol Rep (2013) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类; 1:1000
赛默飞世尔 ER抗体(Neomarkers, SP1)被用于免疫组化在人类样品上浓度为1:1000. Clin Med Insights Case Rep (2012) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:100; 图1
赛默飞世尔 ER抗体(NeoMarkers, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:100 (图1). Diagn Pathol (2011) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:50
赛默飞世尔 ER抗体(Neomarker, RM9101-S)被用于免疫组化-石蜡切片在人类样品上浓度为1:50. Breast Cancer Res (2011) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类; 图1
赛默飞世尔 ER抗体(Lab Vision, SP1)被用于免疫印迹在人类样品上 (图1). Endocr Relat Cancer (2010) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 表1
赛默飞世尔 ER抗体(Labvision, SP1)被用于免疫组化-石蜡切片在人类样品上 (表1). Pathology (2010) ncbi
未注明
  • 免疫组化; 人类
为证明在原发性乳腺癌中EMP3基因的过量表达是否与DNA的甲基化无关,将Zymed提供的单克隆小鼠抗人雌激素受体抗体(clone 1D5)用于免疫组化实验中。J Korean Med Sci (2009) ncbi
未注明
  • 免疫印迹; 人类
为了研究参与调控SRC-3/AIB1辅激活物的功能与降解的基本磷酸酶和决定SRC-3/AIB1降解的磷酸化降解决定子,采用了Thermo Scientific的抗ER抗体进行免疫印迹实验。Mol Cell (2008) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类; 1:400; 表3
赛默飞世尔 ER抗体(Thermo Scientific, SP1)被用于免疫组化-石蜡切片在人类样品上浓度为1:400 (表3). Histopathology (2008) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-F; 人类; 1:100
赛默飞世尔 ER抗体(Lab Vision, 6F11)被用于免疫组化-冰冻切片在人类样品上浓度为1:100. Am J Clin Pathol (2008) ncbi
兔 单克隆(Sp1)
  • 细胞化学; 人类; 图5
赛默飞世尔 ER抗体(Neomarkers, SP1)被用于免疫细胞化学在人类样品上 (图5). Breast Cancer Res (2007) ncbi
小鼠 单克隆(1D5)
  • 免疫组化-P; 人类; 1:200
赛默飞世尔 ER抗体(Zymed, ID5)被用于免疫组化-石蜡切片在人类样品上浓度为1:200. Cancer Cell Int (2006) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-P; 人类; 1:80; 图6
赛默飞世尔 ER抗体(Zymed, 6F11)被用于免疫组化-石蜡切片在人类样品上浓度为1:80 (图6). Am J Surg Pathol (2004) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-P; 大鼠; 表1
赛默飞世尔 ER抗体(Zymed, 6F11)被用于免疫组化-石蜡切片在大鼠样品上 (表1). Biol Reprod (2004) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-P; 人类; 表2
赛默飞世尔 ER抗体(Zymed, 6F11)被用于免疫组化-石蜡切片在人类样品上 (表2). Int J Gynecol Cancer (2003) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-P; 人类; 表1
赛默飞世尔 ER抗体(Zymed, 6F11)被用于免疫组化-石蜡切片在人类样品上 (表1). Histopathology (2002) ncbi
小鼠 单克隆(6F11)
  • 免疫组化-P; 人类; 图1
赛默飞世尔 ER抗体(Zymed, 6F11)被用于免疫组化-石蜡切片在人类样品上 (图1). Int J Gynecol Pathol (2001) ncbi
小鼠 单克隆(AER314)
  • 免疫印迹 (基因敲除); 人类; 图4
赛默飞世尔 ER抗体(Neomarkers, AER314)被用于免疫印迹 (基因敲除)在人类样品上 (图4). Clin Cancer Res (1996) ncbi
圣克鲁斯生物技术
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图2
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹在人类样品上 (图2). PLoS ONE (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫组化-P; 人类; 1:500; 图1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫组化-石蜡切片在人类样品上浓度为1:500 (图1). Oncol Lett (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 图1
圣克鲁斯生物技术 ER抗体(santa Cruz, sc-8002)被用于免疫印迹在人类样品上 (图1). Breast Cancer Res (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:750; 图1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹在人类样品上浓度为1:750 (图1). Breast Cancer Res Treat (2016) ncbi
小鼠 单克隆(F-10)
  • ChIP; 人类; 图3
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-8002X)被用于染色质免疫沉淀 在人类样品上 (图3). PLoS ONE (2016) ncbi
小鼠 单克隆(C-311)
  • 免疫印迹 (基因敲减); 小鼠; 1:1000; 图7
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc787)被用于免疫印迹 (基因敲减)在小鼠样品上浓度为1:1000 (图7). Sci Rep (2016) ncbi
大鼠 单克隆(H226)
  • 免疫组化-P; baboons; 图4
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-53493)被用于免疫组化-石蜡切片在baboons样品上 (图4). Oncotarget (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹 (基因敲除); 人类; 图1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹 (基因敲除)在人类样品上 (图1). PLoS ONE (2016) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类; 1:1000; 图6
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于免疫印迹在人类样品上浓度为1:1000 (图6). Breast Cancer Res (2016) ncbi
小鼠 单克隆(D-12)
  • 细胞化学; 人类; 图1
  • 免疫印迹; 人类; 图5
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc8005)被用于免疫细胞化学在人类样品上 (图1) 和 免疫印迹在人类样品上 (图5). Oncogene (2016) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:200; 图2
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹在人类样品上浓度为1:200 (图2). J Immunol Res (2015) ncbi
小鼠 单克隆(D-12)
  • ChIP; 人类; 图4
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005X)被用于染色质免疫沉淀 在人类样品上 (图4). Oncogene (2016) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类; 图1
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于免疫印迹在人类样品上 (图1). Front Endocrinol (Lausanne) (2015) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 小鼠; 1:300
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于免疫印迹在小鼠样品上浓度为1:300. Reprod Sci (2016) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-8005)被用于免疫印迹在人类样品上. J Biol Chem (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:1000; 图4
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002 F-10)被用于免疫印迹在人类样品上浓度为1:1000 (图4). PLoS ONE (2015) ncbi
小鼠 单克隆(2Q418)
  • ChIP; 人类; 图5
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, 2Q418)被用于染色质免疫沉淀 在人类样品上 (图5). Biochim Biophys Acta (2015) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹; 人类
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于免疫印迹在人类样品上. Cell Oncol (Dordr) (2015) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 小鼠; 图6
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-8002)被用于免疫印迹在小鼠样品上 (图6). elife (2014) ncbi
小鼠 单克隆(2Q418)
  • 免疫印迹; 人类; 1:500; 图3
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-71064)被用于免疫印迹在人类样品上浓度为1:500 (图3). Mol Autism (2014) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:200
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹在人类样品上浓度为1:200. Cell Oncol (Dordr) (2014) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 小鼠
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002X)被用于免疫印迹在小鼠样品上. J Immunol (2014) ncbi
小鼠 单克隆(D-12)
  • 免疫组化-P; 人类; 1:75
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于免疫组化-石蜡切片在人类样品上浓度为1:75. Int J Cancer (2014) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹在人类样品上. Nucleic Acids Res (2014) ncbi
  • 免疫印迹; 人类
为了研究在管腔乳腺癌中雌激素敏感性以及抗雌激素抗性的获得,采用了Santa Cruz 的抗ERa抗体进行了western blot实验。PLoS Biol (2012) ncbi
未注明
  • 免疫印迹; 人类
为了研究雌激素受体或者他的辅因子的过量表达常常与乳腺癌有关,本文研究了辅因子LRP16怎样调节雌激素受体的过量表达和分化,采用了Santa Cruz Biotechnology公司雌激素受体抗体,进行蛋白质印记实验。BMC Cell Biol (2009) ncbi
小鼠 单克隆(D-12)
  • 免疫沉淀; 小鼠; 图1
圣克鲁斯生物技术 ER抗体(Santa Cruz Biotechnology, sc-8005)被用于免疫沉淀在小鼠样品上 (图1). Mol Cell (2009) ncbi
未注明
  • 免疫印迹; 人类
为了研究OTUB1同ERa的关系,采用了Santa Cruz公司的ERa抗体,进行了蛋白印记实验。J Biol Chem (2009) ncbi
未注明
  • 免疫印迹; 人类
为研究Lipocalin2蛋白对乳腺癌发展的影响,将Santa Cruz提供的抗雌激素受体alpha抗体用于蛋白免疫印迹实验中。Proc Natl Acad Sci U S A (2009) ncbi
未注明
  • 免疫组化; 人类
为研究snail1在成骨细胞分化过程中对骨聚集所起的控制作用,使用了Santa Cruz公司的抗雌激素受体抗体来进行免疫组化分析。EMBO J (2009) ncbi
未注明
  • ChIP; 人类
为研究snail1在成骨细胞分化过程中对骨聚集所起的控制作用,使用了Santa Cruz公司的抗ER抗体来进行ChIP分析。EMBO J (2009) ncbi
未注明
  • 免疫印迹; 人类
为了研究AID的C末端结构域与ACF的相互作用以及AID在免疫球蛋白类别转换重组中的功能,使用了Santa Cruz Biotechnology公司的抗雌激素受体(ERalpha)多克隆抗体HC-20来进行免疫印迹分析。Proc Natl Acad Sci U S A (2009) ncbi
未注明
  • 免疫组化; 人类
为了研究神经降压素受体1通路在导管型乳腺癌演变中的作用,采用Santa Cruz公司的ER-alpha单克隆抗体产品,进行了免疫组化实验。 PLoS ONE (2009) ncbi
未注明
  • 免疫印迹; 人类
  • 免疫沉淀; 人类
使用Santa Cruz 生物公司的的抗ERα抗体(HC-20)进行免疫印迹和染色质免疫沉淀实验来研究在ER阳性人乳腺癌细胞系(T47D and ZR-75-1)中降低BRCA1水平和对Tam反应性中的潜在联系。.Oncogene (2009) ncbi
  • 免疫沉淀; 人类
为了研究卵巢中GIOT-4对雌激素受体蛋白beta的共激活作用,在免疫沉淀反应中使用了Santa Cruz Biotechnology公司的抗ERα抗体。Mol Cell Biol (2009) ncbi
未注明
  • 免疫印迹; 人类
为了研究参与调控SRC-3/AIB1辅激活物的功能与降解的基本磷酸酶和决定SRC-3/AIB1降解的磷酸化降解决定子,采用了Santa Cruz的抗磷酸化ER(S118)抗体进行免疫印迹实验。Mol Cell (2008) ncbi
未注明
  • 细胞化学; 人类
为了研究Grxl调控线粒体机能的潜在机制,使用了Santa Cruz Biotechnology公司的雌激素受体α抗体,进行了免疫细胞化学实验。PLoS ONE (2008) ncbi
未注明
  • 免疫印迹; 人类
  • ChIP; 人类
为了研究乳腺癌细胞中雌激素对CD24的调节,采用了Santa Cruz公司的抗ER alpha抗体进行了免疫印记(1:1000)和染色质免疫共沉淀实验。Int J Cancer (2008) ncbi
未注明
  • 免疫印迹; 人类
为了分析在AP-1元件侧的顺式作用位点对基础和雌性激素依赖的BRCA1转录的调控的作用,采用了Santa Cruz公司的ER-α抗体进行了蛋白印迹实验。Breast Cancer Res (2008) ncbi
未注明
  • 免疫印迹; 人类
为了研究植物雌激素如染料木素如何影响雌激素受体调节的基因表达,采用了Santa Cruz生物技术公司的雌激素受体α进行了蛋白印迹实验。Mol Endocrinol (2008) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类
为了研究SOD1对雌性激素应答基因的活化的作用,采用了Santa Cruz生物技术公司的雌激素受体α抗体进行了蛋白印迹实验。Mol Endocrinol (2008) ncbi
未注明
  • 免疫印迹; 人类
  • 免疫沉淀; 人类
为了证明Erα与β-catenin/Lef-1/Tcf-3信号的整合,是子宫中雌激素依赖的内源基因调控的必要过程,采用了Santa Cruz Biotechnology的经亲和纯化的Erα抗体,进行免疫沉淀反应和蛋白质印迹Mol Endocrinol (2008) ncbi
未注明
  • ChIP; 人类
为了说明CBP计量是ER-和NFκB-信号通路基因独特性信号整合调控的重要的控制器,采用Santa Cruz公司ERα抗体,进行免疫沉淀反应实验。Mol Endocrinol (2008) ncbi
小鼠 单克隆(D-12)
  • 免疫印迹 (基因敲减); 人类
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8005)被用于免疫印迹 (基因敲减)在人类样品上. Mol Endocrinol (2007) ncbi
未注明
  • 免疫印迹; 人类
为了研究辅伴侣蛋白P23 在雌激素受体α的信号转导中的不同调节作用,采用了Santa Cruz Biotechnology公司雌激素受体α抗体,进行蛋白质印记实验。Mol Cell Biol (2006) ncbi
小鼠 单克隆(F-10)
  • 免疫印迹; 人类; 1:400; 图6
圣克鲁斯生物技术 ER抗体(Santa Cruz, sc-8002)被用于免疫印迹在人类样品上浓度为1:400 (图6). Oncogene (2005) ncbi
艾博抗(上海)贸易有限公司
兔 单克隆(Sp1)
  • 免疫组化-F; 小鼠; 1:100; 图S3
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab27595)被用于免疫组化-冰冻切片在小鼠样品上浓度为1:100 (图S3). Nat Commun (2016) ncbi
兔 单克隆(Sp1)
  • 细胞化学; 小鼠
艾博抗(上海)贸易有限公司 ER抗体(Abcam, AB27595)被用于免疫细胞化学在小鼠样品上. PLoS ONE (2015) ncbi
兔 单克隆(Sp1)
  • 细胞化学; 人类; 1:100
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab16660)被用于免疫细胞化学在人类样品上浓度为1:100. Front Cell Dev Biol (2015) ncbi
兔 单克隆(Sp1)艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab27595)被用于. Nat Commun (2015) ncbi
兔 单克隆(Sp1)
  • 免疫印迹; 人类
艾博抗(上海)贸易有限公司 ER抗体(Abcam, SP-1)被用于免疫印迹在人类样品上. Breast Cancer Res (2014) ncbi
兔 单克隆(Sp1)
  • 免疫组化-P; 人类
艾博抗(上海)贸易有限公司 ER抗体(Abcam, ab16660)被用于免疫组化-石蜡切片在人类样品上. PLoS ONE (2014) ncbi
Active Motif
小鼠 单克隆(F3)
  • ChIP; 人类; 图6
Active Motif ER抗体(Active Motif, 61035)被用于染色质免疫沉淀 在人类样品上 (图6). Nat Commun (2016) ncbi
小鼠 单克隆(F3)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类; 1:500
Active Motif ER抗体(Active Motif, 61035)被用于免疫沉淀在人类样品上 和 免疫印迹在人类样品上浓度为1:500. Lupus (2013) ncbi
武汉三鹰
兔 多克隆
  • 免疫组化-P; 牛; 1:50; 图6
武汉三鹰 ER抗体(Proteintech, 21244-1-AP)被用于免疫组化-石蜡切片在牛样品上浓度为1:50 (图6). Sci Rep (2016) ncbi
Bethyl
兔 多克隆
  • 免疫印迹 (基因敲减); 人类
Bethyl ER抗体(Bethyl Labs, A300-498A)被用于免疫印迹 (基因敲减)在人类样品上. Mol Oncol (2016) ncbi
赛信通(上海)生物试剂有限公司
兔 单克隆(D8H8)
  • 免疫印迹; 人类; 1:1000; 表s6
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 8644)被用于免疫印迹在人类样品上浓度为1:1000 (表s6). PLoS Genet (2016) ncbi
小鼠 单克隆(16J4)
  • FC; 牛; 1:50; 图6
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, 2511S)被用于流式细胞仪在牛样品上浓度为1:50 (图6). Mediators Inflamm (2016) ncbi
小鼠 单克隆(16J4)
  • 免疫组化-P; 人类; 1:50; 图s1
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2511)被用于免疫组化-石蜡切片在人类样品上浓度为1:50 (图s1). BMC Cancer (2016) ncbi
兔 多克隆
  • 免疫印迹; 人类; 图5
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2517S)被用于免疫印迹在人类样品上 (图5). Oncogene (2016) ncbi
小鼠 单克隆(16J4)
  • 免疫印迹; 人类; 图4
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2511S)被用于免疫印迹在人类样品上 (图4). Oncogene (2016) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 大鼠; 1:500; 图s2
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, 8644)被用于免疫印迹在大鼠样品上浓度为1:500 (图s2). Life Sci (2015) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类; 图1
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signal, D8H8)被用于免疫印迹在人类样品上 (图1). PLoS ONE (2015) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, 8644)被用于免疫印迹在人类样品上. Cell Death Dis (2014) ncbi
兔 单克隆(D8H8)
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling Technology, D8H8)被用于免疫印迹在人类样品上. Cell Biochem Biophys (2015) ncbi
  • 免疫印迹; 人类
赛信通(上海)生物试剂有限公司 ER抗体(Cell Signaling, 2511)被用于免疫印迹在人类样品上. Oncogene (2014) ncbi
未注明
  • 免疫印迹; 人类
使用Cell Signaling技术公司的抗磷酸化ERα (S118)进行免疫印迹实验来研究在ER阳性人乳腺癌细胞系(T47D and ZR-75-1)中降低BRCA1水平和对Tam反应性中的潜在联系。 Oncogene (2009) ncbi
未注明
  • 免疫印迹; 人类
为了分析在AP-1元件侧的顺式作用位点对基础和雌性激素依赖的BRCA1转录的调控的作用,采用了细胞信号公司的磷酸化ER-α(Ser118)抗体进行了蛋白印迹实验。Breast Cancer Res (2008) ncbi
徕卡显微系统(上海)贸易有限公司
小鼠 单克隆
  • 免疫组化; 人类; 1:50
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Biosystems, 6F11)被用于免疫组化在人类样品上浓度为1:50. Hum Pathol (2015) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:400
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, NCL-L-ER-6F11)被用于免疫组化在人类样品上浓度为1:400. Pathol Oncol Res (2015) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:200
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Microsystems, 6 F11)被用于免疫组化在人类样品上浓度为1:200. J Ovarian Res (2015) ncbi
小鼠 单克隆
  • 免疫组化-P; 大鼠
徕卡显微系统(上海)贸易有限公司 ER抗体(Novacastra, NCL-L-ER-6F11)被用于免疫组化-石蜡切片在大鼠样品上. Prostate (2015) ncbi
小鼠 单克隆
  • 免疫组化-P; 人类
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, NCL-L-ER-6F11)被用于免疫组化-石蜡切片在人类样品上. BMC Cancer (2014) ncbi
小鼠 单克隆
  • 免疫组化-P; 人类
徕卡显微系统(上海)贸易有限公司 ER抗体(Germany Leica, 6F11)被用于免疫组化-石蜡切片在人类样品上. Cell Biochem Biophys (2015) ncbi
小鼠 单克隆
  • 免疫组化-P; 人类; 1:35
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于免疫组化-石蜡切片在人类样品上浓度为1:35. Hum Pathol (2014) ncbi
小鼠 单克隆
  • 免疫组化-P; 人类; 1:200
徕卡显微系统(上海)贸易有限公司 ER抗体(Leica Microsystems, 6F11)被用于免疫组化-石蜡切片在人类样品上浓度为1:200. Virchows Arch (2014) ncbi
小鼠 单克隆
  • 免疫组化; 人类
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于免疫组化在人类样品上. Breast Cancer Res Treat (2014) ncbi
小鼠 单克隆
  • 免疫组化; 人类; 1:200
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于免疫组化在人类样品上浓度为1:200. Horm Cancer (2014) ncbi
小鼠 单克隆
  • 免疫组化-P; 人类; 1:300
徕卡显微系统(上海)贸易有限公司 ER抗体(Novocastra, 6F11)被用于免疫组化-石蜡切片在人类样品上浓度为1:300. Korean J Pathol (2013) ncbi
未注明
  • 免疫组化; 人类
为了研究c-Src激酶是否会促使非典型小叶增生或小叶原位癌转变为浸润性小叶癌,使用了Novocastra公司的抗雌激素受体抗体(1:80)进行免疫荧光实验。Breast Cancer Res (2009) ncbi
未注明
  • 免疫组化; 人类
为了研究ISG15是人乳腺肿瘤的全新的标记基因,采用了Novocastra的抗estrogen receptor (ER)抗体以1:20稀释进行免疫组化实验。Breast Cancer Res (2008) ncbi
未注明
  • 免疫组化; 人类
为了研究CRYAB在乳腺癌中的表达,采用了Novocastra公司的抗ER alpha抗体(6F11)进行了免疫组织化学实验。Ann Diagn Pathol (2008) ncbi
默克密理博中国
小鼠 单克隆
  • 免疫组化; 小鼠; 1:100; 图2
默克密理博中国 ER抗体(Millipore, 17-603)被用于免疫组化在小鼠样品上浓度为1:100 (图2). Sci Rep (2016) ncbi
兔 多克隆
  • 免疫印迹; 人类; 1:1000
  • 细胞化学; 人类; 1:100
默克密理博中国 ER抗体(Upstate Merck Millipore, #07-481)被用于免疫印迹在人类样品上浓度为1:1000 和 免疫细胞化学在人类样品上浓度为1:100. Breast Cancer Res (2014) ncbi
未注明
  • 免疫印迹; 人类
结合计算机模拟实验,模拟实验结果的检验,以及蛋白相互作用网络的反向工程实验来确认新的曲妥单抗抗乳腺癌的潜在治疗策略,将Upstate提供的兔抗ER alpha抗体(目录号:05-820)用于蛋白免疫印迹。BMC Syst Biol (2009) ncbi
Spring Bioscience Corp.
兔 多克隆
  • 免疫组化-P; 小鼠; 图4
  • 免疫组化 (基因敲减); 小鼠; 1:200; 图4f
Spring Bioscience Corp. ER抗体(Spring Bioscience, E1644)被用于免疫组化-石蜡切片在小鼠样品上 (图4) 和 免疫组化 (基因敲减)在小鼠样品上浓度为1:200 (图4f). Diabetes (2015) ncbi
兔 单克隆(Sp1)
  • 免疫组化; 人类
为了研究c-erbB-2的表达量对子宫内膜癌的影响,使用了Spring Bioscience公司的ER兔单抗(M3011, 1:100稀释)来进行免疫组化实验。Diagn Pathol (2010) ncbi
安迪生物R&D
羊 多克隆
  • PLA; 人类
安迪生物R&D ER抗体(R&D Systems, AF5715)被用于proximity ligation assay在人类样品上. BMC Cancer (2014) ncbi
Roche Applied Science
未注明
  • 免疫组化; 人类
为了研究CD109表达在基底细胞样乳腺癌的意义,采用了Ventana的ER抗体进行了免疫组化实验。Pathol Int (2008) ncbi
丹科医疗器械技术服务(上海)有限公司
未注明
  • 免疫组化; 人类
为了研究雌激素受体beta激活的凋亡的调节机制和它的拮抗物在癌症治疗中的作用,使用了DAKO公司的抗ERa抗体来进行免疫组化试验。Proc Natl Acad Sci U S A (2010) ncbi
未注明
  • 免疫组化; 人类
为了研究雌性激素受体Beta在促进良性前列腺增生和前列腺癌细胞凋亡中发挥的作用,作者使用DAKO公司的抗ERa抗体进行免疫组化实验。Proc Natl Acad Sci U S A (2010) ncbi
未注明
  • 免疫组化; 人类
为了说明CENP-F高表达是原发性乳腺癌的预后指标,使用了Dako公司的ER抗体来进行免疫组化实验。BMC Cancer (2008) ncbi
未注明
  • 免疫组化; 人类
为了研究输尿管子宫内膜异位症,采用了DAKO的抗ER抗体进行免疫组化实验。Hum Pathol (2008) ncbi
未注明
  • 免疫组化; 人类
为了研究乳腺癌的病理学类型与过表达的、改变的局限性的非典型蛋白激酶C lambda/iota的相互关系,采用了Dako Cytomation的鼠抗ER(1D5,1/50)抗体进行免疫组织化学试验。Hum Pathol (2008) ncbi
未注明
  • EMSA; 人类
为了研究乳腺癌细胞中雌激素对CD24的调节,采用了DakoCytomation公司的抗ER alpha单克隆抗体进行了胶迁移实验。Int J Cancer (2008) ncbi
未注明
  • 免疫组化; 人类
为了研究在乳腺癌中淋巴结(LN)转移与CD1a+单核细胞的关系,以及CD1a的作用,采用了Dako的单克隆抗oestrogen(ER)(clone 1D5)抗体进行免疫组织化学试验。Histopathology (2008) ncbi
文章列表
  1. Barbara Mair et al. (2016). "Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity".PMID 27588951
  2. Qi Chen et al. (2016). "Endothelial cells are progenitors of cardiac pericytes and vascular smooth muscle cells".PMID 27516371
  3. Ahmed E Dhamad et al. (2016). "Systematic Proteomic Identification of the Heat Shock Proteins (Hsp) that Interact with Estrogen Receptor Alpha (ERα) and Biochemical Characterization of the ERα-Hsp70 Interaction".PMID 27483141
  4. Renquan Lu et al. (2016). "COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR".PMID 27375289
  5. Adriana Priscila Trapé et al. (2016). "Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel".PMID 27313785
  6. Gloria M Calaf et al. (2016). "Ras protein expression as a marker for breast cancer".PMID 27284366
  7. Bingjian Lu et al. (2016). "Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases".PMID 27260518
  8. Marco Ávila-Rodriguez et al. (2016). "Tibolone protects astrocytic cells from glucose deprivation through a mechanism involving estrogen receptor beta and the upregulation of neuroglobin expression".PMID 27250720
  9. Nikiana Simigdala et al. (2016). "Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer".PMID 27246191
  10. Alexander Nguyen et al. (2016). "Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness".PMID 27138336
  11. A Thakkar et al. (2016). "Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer".PMID 27120467
  12. Atsushi Ideta et al. (2016). "Generation of exogenous germ cells in the ovaries of sterile NANOS3-null beef cattle".PMID 27117862
  13. Ivan Medina-Estrada et al. (2016). "Anti-Inflammatory and Antimicrobial Effects of Estradiol in Bovine Mammary Epithelial Cells during Staphylococcus aureus Internalization".PMID 27034592
  14. Jonathan C Irish et al. (2016). "Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERα in SUM-44 breast cancer cells and is associated with ERα over-expression in breast cancer".PMID 27005559
  15. Luisa Carbognin et al. (2016). "Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer".PMID 27000271
  16. Huda Omar Ali et al. (2016). "Oestrogens Downregulate Tissue Factor Pathway Inhibitor through Oestrogen Response Elements in the 5'-Flanking Region".PMID 26999742
  17. Mohammad F Al-Harras et al. (2016). "Polymorphisms of glutathione S-transferase π 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility".PMID 26998146
  18. Quang Kim Tran et al. (2016). "Estrogen Enhances Linkage in the Vascular Endothelial Calmodulin Network via a Feedforward Mechanism at the G Protein-coupled Estrogen Receptor 1".PMID 26987903
  19. Antonis Koussounadis et al. (2016). "Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models".PMID 26964739
  20. Yichao Zhao et al. (2016). "YiXin-Shu, a ShengMai-San-based traditional Chinese medicine formula, attenuates myocardial ischemia/reperfusion injury by suppressing mitochondrial mediated apoptosis and upregulating liver-X-receptor α".PMID 26964694
  21. Soo Yeon Kim et al. (2016). "Asymptomatic Benign Papilloma Without Atypia Diagnosed at Ultrasonography-Guided 14-Gauge Core Needle Biopsy: Which Subgroup can be Managed by Observation?".PMID 26920388
  22. Hareesh B Nair et al. (2016). "An efficient model of human endometriosis by induced unopposed estrogenicity in baboons".PMID 26908459
  23. Tamar Kavlashvili et al. (2016). "Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer".PMID 26859414
  24. Valentina Vacca et al. (2016). "17beta-estradiol counteracts neuropathic pain: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice".PMID 26742647
  25. Catherine L Piggin et al. (2016). "ELF5 isoform expression is tissue-specific and significantly altered in cancer".PMID 26738740
  26. Saba Mohamed El-Gendi et al. (2016). "Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma".PMID 26597806
  27. Agla J Fridriksdottir et al. (2015). "Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture".PMID 26564780
  28. A Alayev et al. (2016). "mTORC1 directly phosphorylates and activates ERα upon estrogen stimulation".PMID 26522726
  29. María Genoveva González-Morán et al. (2015). "Immunohistochemical localization of progesterone receptor isoforms and estrogen receptor alpha in the chicken oviduct magnum during development".PMID 26519127
  30. Ewa Wunsch et al. (2015). "Liver Expression of Sulphotransferase 2A1 Enzyme Is Impaired in Patients with Primary Sclerosing Cholangitis: Lack of the Response to Enhanced Expression of PXR".PMID 26504856
  31. J O'Shaughnessy et al. (2016). "Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer".PMID 26504153
  32. Ioannis Kokkinopoulos et al. (2015). "Single-Cell Expression Profiling Reveals a Dynamic State of Cardiac Precursor Cells in the Early Mouse Embryo".PMID 26469858
  33. N S Radhika et al. (2015). "Neonatal exposure to 17β-estradiol down-regulates the expression of synaptogenesis related genes in selected brain regions of adult female rats".PMID 26409312
  34. Yoon Yang Jung et al. (2015). "Expression of Lipid Metabolism-Related Proteins in Metastatic Breast Cancer".PMID 26334757
  35. Raquel G Coelho et al. (2015). "Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma".PMID 26320188
  36. Gisela G Slaats et al. (2015). "DNA replication stress underlies renal phenotypes in CEP290-associated Joubert syndrome".PMID 26301811
  37. P Y Hsu et al. (2016). "Spatiotemporal control of estrogen-responsive transcription in ERα-positive breast cancer cells".PMID 26300005
  38. J Malaterre et al. (2016). "Intestinal-specific activatable Myb initiates colon tumorigenesis in mice".PMID 26300002
  39. Nilgun Kapucuoglu et al. (2015). "The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer".PMID 26298632
  40. Koko Adachi et al. (2015). "Intracrine steroid production and mammalian target of rapamycin pathways in pulmonary lymphangioleiomyomatosis".PMID 26298231
  41. Yong Qu Zhang et al. (2015). "Over-Expressed Twist Associates with Markers of Epithelial Mesenchymal Transition and Predicts Poor Prognosis in Breast Cancers via ERK and Akt Activation".PMID 26295469
  42. Maria Magdalena Montt-Guevara et al. (2015). "Estetrol Modulates Endothelial Nitric Oxide Synthesis in Human Endothelial Cells".PMID 26257704
  43. Jean McBryan et al. (2015). "Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy".PMID 26240272
  44. K Bacallao et al. (2016). "Levels of Regulatory Proteins Associated With Cell Proliferation in Endometria From Untreated Patients Having Polycystic Ovarian Syndrome With and Without Endometrial Hyperplasia".PMID 26239387
  45. A R Rowson-Hodel et al. (2015). "Neoplastic transformation of porcine mammary epithelial cells in vitro and tumor formation in vivo".PMID 26228788
  46. V Felzen et al. (2015). "Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 function".PMID 26158518
  47. Fiorita Gonzales Lopes Mundim et al. (2015). "MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases".PMID 26137258
  48. Sai Yin Cheung et al. (2015). "Role of epithelial-mesenchymal transition markers in triple-negative breast cancer".PMID 26123543
  49. Valerie Cui Yun Koh et al. (2015). "Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients".PMID 26077641
  50. Piotr Winczura et al. (2015). "Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients".PMID 26062800
  51. Donna Catherine Ferguson et al. (2015). "Comparative analysis of Rb1, P16 and ER as diagnostic, prognostic and potential targets for therapeutic agents in ovarian epithelial tumors: an immunohistochemical study of 130 ovarian carcinomas".PMID 26043844
  52. Yixing Yuchi et al. (2015). "Estrogen Receptor α Regulates β-Cell Formation During Pancreas Development and Following Injury".PMID 26015547
  53. Rafael de Deus Moura et al. (2015). "Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old".PMID 25998784
  54. Yun Teng et al. (2015). "Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells".PMID 25969534
  55. C C Nwafor et al. (2015). "Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience".PMID 25966732
  56. Henrik Frithiof et al. (2015). "A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation".PMID 25896421
  57. Hua Zhao et al. (2015). "Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment".PMID 25885600
  58. María de los Ángeles Carrasco-Ruiz et al. (2015). "Aromatase expression is linked to estrogenic sensitivity of periurethral muscles in female rabbits".PMID 25850953
  59. Jonathan K Lee et al. (2015). "Age and the means of bypassing stasis influence the intrinsic subtype of immortalized human mammary epithelial cells".PMID 25815289
  60. I G Tkalia et al. (2015). "The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats".PMID 25804228
  61. Julie Carnesecchi et al. (2015). "Estrogens induce rapid cytoskeleton re-organization in human dermal fibroblasts via the non-classical receptor GPR30".PMID 25781607
  62. Yvette P Geels et al. (2015). "Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium".PMID 25773202
  63. Keun Yong Eom et al. (2016). "The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer".PMID 25761481
  64. Orsolya Rusz et al. (2015). "One-Year Neoadjuvant Endocrine Therapy in Breast Cancer".PMID 25753983
  65. Sewha Kim et al. (2015). "Differential expression of lipid metabolism-related proteins in different breast cancer subtypes".PMID 25751270
  66. Imran Hussain et al. (2015). "Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer".PMID 25725483
  67. Sandra Heskamp et al. (2015). "Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients".PMID 25680198
  68. Ming Liang Oon et al. (2015). "Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast".PMID 25677743
  69. Michiel Simons et al. (2015). "A patient with a noninvasive mucinous ovarian borderline tumor presenting with late pleural metastases".PMID 25675183
  70. Asuman Argon et al. (2014). "The effect of freezing on the immunoprofile of breast carcinoma cells".PMID 25667788
  71. Stine Hole et al. (2015). "New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane".PMID 25625755
  72. Amr E Ammar et al. (2015). "The effect of pomegranate fruit extract on testosterone-induced BPH in rats".PMID 25620586
  73. Qiaozhen Liu et al. (2015). "Genetic targeting of sprouting angiogenesis using Apln-CreER".PMID 25597280
  74. Vassilis Papanikolaou et al. (2015). "Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes".PMID 25539992
  75. Kai Doberstein et al. (2014). "L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor".PMID 25510351
  76. Z J P Yang et al. (2015). "p53 suppresses muscle differentiation at the myogenin step in response to genotoxic stress".PMID 25501595
  77. Jing Liu et al. (2015). "Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast".PMID 25476498
  78. Maaike P A Van Bragt et al. (2014). "RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells".PMID 25415051
  79. N Ohoka et al. (2014). "Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway".PMID 25375378
  80. Robynn V Schillace et al. (2014). "Estrogen receptor, progesterone receptor, interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations".PMID 25269750
  81. I G Tkalia et al. (2014). "Increase of antitumor activity of cisplatin using agonist of gonadotropin-realising hormone and inhibitor of aromatase on the model of ascites ovarian tumor".PMID 25265352
  82. Irène Baccelli et al. (2014). "Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients".PMID 25230070
  83. Amanda Crider et al. (2014). "Dysregulation of estrogen receptor beta (ERβ), aromatase (CYP19A1), and ER co-activators in the middle frontal gyrus of autism spectrum disorder subjects".PMID 25221668
  84. Filomena M Carvalho et al. (2014). "Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil".PMID 25174527
  85. Ayse Selcen Oguz Erdogan et al. (2014). "ARID3B expression in primary breast cancers and breast cancer-derived cell lines".PMID 25120063
  86. Lv Li et al. (2015). "Expression and localization of estrogen receptor in human breast cancer and its clinical significance".PMID 25113640
  87. Catherine Jensen Peña et al. (2015). "Neonatal overexpression of estrogen receptor-α alters midbrain dopamine neuron development and reverses the effects of low maternal care in female offspring".PMID 25044746
  88. Marjanka J J M Mingels et al. (2014). "High prevalence of atypical hyperplasia in the endometrium of patients with epithelial ovarian cancer".PMID 25015863
  89. Binafsha M Syed et al. (2014). "Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts".PMID 24999743
  90. Anna J Ucher et al. (2014). "Mismatch repair proteins and AID activity are required for the dominant negative function of C-terminally deleted AID in class switching".PMID 24973444
  91. Paul K Wright et al. (2014). "17β-estradiol regulates giant vesicle formation via estrogen receptor-alpha in human breast cancer cells".PMID 24931391
  92. Helena Aguilar et al. (2014). "VAV3 mediates resistance to breast cancer endocrine therapy".PMID 24886537
  93. Mounia Tannour-Louet et al. (2014). "Increased gene copy number of VAMP7 disrupts human male urogenital development through altered estrogen action".PMID 24880616
  94. Nelson G Ordonez et al. (2014). "Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study".PMID 24816068
  95. Frency Varghese et al. (2014). "IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples".PMID 24802416
  96. Shiyan Sui et al. (2014). "Maternal protein restriction during gestation and lactation programs offspring ovarian steroidogenesis and folliculogenesis in the prepubertal gilts".PMID 24787658
  97. Gra a Alexandre-Pires et al. (2014). "Morphological aspects and expression of estrogen and progesterone receptors in the interdigital sinus in cyclic ewes".PMID 24779038
  98. R S van der Post et al. (2014). "HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma".PMID 24711169
  99. P P Wong et al. (2014). "Identification of MAGEA antigens as causal players in the development of tamoxifen-resistant breast cancer".PMID 24662835
  100. Katia Bouchekioua-Bouzaghou et al. (2014). "LKB1 when associated with methylatedERα is a marker of bad prognosis in breast cancer".PMID 24615515
  101. Y Liu et al. (2014). "Lack of correlation of stem cell markers in breast cancer stem cells".PMID 24577057
  102. Ling Gao et al. (2014). "In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor".PMID 24570392
  103. Veronique M Neumeister et al. (2014). "A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue".PMID 24535259
  104. Bence Kővári et al. (2014). "Differential immunostaining of various types of breast carcinomas for growth hormone-releasing hormone receptor - Apocrine epithelium and carcinomas emerging as uniformly positive".PMID 24479854
  105. Mary E Booth et al. (2014). "Steroid hormone receptor expression in breast cancer stroma".PMID 24458844
  106. Nicola J Jordan et al. (2014). "Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro".PMID 24457069
  107. Heae Surng Park et al. (2014). "High EGFR gene copy number predicts poor outcome in triple-negative breast cancer".PMID 24406864
  108. Samaan Samaan et al. (2014). "The Ddx5 and Ddx17 RNA helicases are cornerstones in the complex regulatory array of steroid hormone-signaling pathways".PMID 24275493
  109. Jessica M Faupel-Badger et al. (2014). "Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland".PMID 24249584
  110. Tetsuro Yoshimaru et al. (2013). "Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells".PMID 24051437
  111. Kimihide Kusafuka et al. (2014). "Salivary duct carcinoma with rhabdoid features: report of 2 cases with immunohistochemical and ultrastructural analyses".PMID 24038506
  112. Barbara Dewaele et al. (2014). "Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma".PMID 23959973
  113. Jing Zhang et al. (2013). "An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy".PMID 23826420
  114. K Kourelis et al. (2013). "Negative prognostic factors for head and neck cancer in the young".PMID 23818362
  115. Fernando N Aguiar et al. (2013). "Basal cytokeratin as a potential marker of low risk of invasion in ductal carcinoma in situ".PMID 23778411
  116. Jin Yan Hao et al. (2012). "Accessory breast cancer occurring concurrently with bilateral primary invasive breast carcinomas: a report of two cases and literature review".PMID 23691479
  117. Soyoung Im et al. (2013). "Hedgehog related protein expression in breast cancer: gli-2 is associated with poor overall survival".PMID 23667370
  118. C Palmieri et al. (2013). "Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance".PMID 23652306
  119. Yang Zhao et al. (2014). "Primary acinic cell carcinoma of the breast: a case report and review of the literature".PMID 23564703
  120. Baokai Yang et al. (2013). "Correlation of immunoglobulin G expression and histological subtype and stage in breast cancer".PMID 23554916
  121. J M Ward et al. (2013). "Estradiol differentially regulates calreticulin: a potential link with abnormal T cell function in systemic lupus erythematosus?".PMID 23535532
  122. Natássia C R Corrêa et al. (2013). "Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors".PMID 23404580
  123. Maria Kalyuga et al. (2012). "ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer".PMID 23300383
  124. Filomena M Carvalho et al. (2012). "Leiomyomatosis peritonealis disseminata associated with endometriosis and multiple uterus-like mass: report of two cases".PMID 22661902
  125. Phaik Leng Cheah et al. (2011). "Unusual finding of endocervical-like mucinous epithelium in continuity with urothelium in endocervicosis of the urinary bladder".PMID 21699710
  126. Yvonne Hui Fang Teng et al. (2011). "Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy".PMID 21457545
  127. Louise Maymann Rasmussen et al. (2010). "Prolactin and oestrogen synergistically regulate gene expression and proliferation of breast cancer cells".PMID 20601496
  128. Aylin Ege Gul et al. (2010). "The relationship of cerb B 2 expression with estrogen receptor and progesterone receptor and prognostic parameters in endometrial carcinomas".PMID 20167054
  129. Stephen J McPherson et al. (2010). "Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated".PMID 20133657
  130. Yuanguang Meng et al. (2009). "Keratin 18 attenuates estrogen receptor alpha-mediated signaling by sequestering LRP16 in cytoplasm".PMID 20035625
  131. Anthony S Y Leong et al. (2010). "Citraconic anhydride: a new antigen retrieval solution".PMID 20025485
  132. Kaoru Yamagata et al. (2009). "Maturation of microRNA is hormonally regulated by a nuclear receptor".PMID 19854141
  133. Donghui Zou et al. (2009). "Increased levels of active c-Src distinguish invasive from in situ lobular lesions".PMID 19583841
  134. Vladimir Stanisic et al. (2009). "OTU Domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity".PMID 19383985
  135. Wei Zhou et al. (2009). "EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations".PMID 19270820
  136. Jiang Yang et al. (2009). "Lipocalin 2 promotes breast cancer progression".PMID 19237579
  137. Cristina A de Frutos et al. (2009). "Snail1 controls bone mass by regulating Runx2 and VDR expression during osteoblast differentiation".PMID 19197242
  138. Taichiro Nonaka et al. (2009). "Carboxy-terminal domain of AID required for its mRNA complex formation in vivo".PMID 19196959
  139. Sandra Dupouy et al. (2009). "The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression".PMID 19156213
  140. Ozgur Sahin et al. (2009). "Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance".PMID 19118495
  141. Shigeto Ueda et al. (2008). "Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer".PMID 19102762
  142. J Wen et al. (2009). "Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions".PMID 18997820
  143. Madoka Kouzu-Fujita et al. (2009). "Coactivation of estrogen receptor beta by gonadotropin-induced cofactor GIOT-4".PMID 18981223
  144. Chao Li et al. (2008). "Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover".PMID 18922467
  145. Nuran Bektas et al. (2008). "The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer".PMID 18627608
  146. Uzma Saeed et al. (2008). "Knockdown of cytosolic glutaredoxin 1 leads to loss of mitochondrial membrane potential: implication in neurodegenerative diseases".PMID 18560520
  147. Maha Al-Khawaja et al. (2008). "Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases".PMID 18538172
  148. Yasuyuki Kojima et al. (2008). "The overexpression and altered localization of the atypical protein kinase C lambda/iota in breast cancer correlates with the pathologic type of these tumors".PMID 18538170
  149. T H Kim et al. (2008). "Down-regulation of claudin-2 in breast carcinomas is associated with advanced disease".PMID 18479414
  150. Masaki Hasegawa et al. (2008). "CD109 expression in basal-like breast carcinoma".PMID 18429827
  151. Benny Abraham Kaipparettu et al. (2008). "Estrogen-mediated downregulation of CD24 in breast cancer cells".PMID 18404683
  152. Jennifer K Hockings et al. (2008). "Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene".PMID 18377656
  153. Shan Rong Shi et al. (2008). "Evaluation of the value of frozen tissue section used as "gold standard" for immunohistochemistry".PMID 18285257
  154. Edmund C Chang et al. (2008). "Estrogen Receptors alpha and beta as determinants of gene expression: influence of ligand, dose, and chromatin binding".PMID 18258689
  155. Abhi K Rao et al. (2008). "Effects of Cu/Zn superoxide dismutase on estrogen responsiveness and oxidative stress in human breast cancer cells".PMID 18258688
  156. Sanhita Ray et al. (2008). "Cooperative control via lymphoid enhancer factor 1/T cell factor 3 and estrogen receptor-alpha for uterine gene regulation by estrogen".PMID 18202148
  157. G La Rocca et al. (2008). "CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome".PMID 18184269
  158. Stephanie M Sitterding et al. (2008). "AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas".PMID 18164413
  159. Kendall W Nettles et al. (2008). "CBP Is a dosage-dependent regulator of nuclear factor-kappaB suppression by the estrogen receptor".PMID 17932106
  160. Archana Dhasarathy et al. (2007). "The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha".PMID 17761946
  161. Stephan Duss et al. (2007). "An oestrogen-dependent model of breast cancer created by transformation of normal human mammary epithelial cells".PMID 17573968
  162. Ellinor Oxelmark et al. (2006). "The cochaperone p23 differentially regulates estrogen receptor target genes and promotes tumor cell adhesion and invasion".PMID 16809759
  163. Krishna Rao et al. (2006). "Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells".PMID 16729884
  164. Laundette P Jones et al. (2005). "Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer".PMID 15750629
  165. Kuan Ting Kuo et al. (2004). "Epithelioid trophoblastic tumor of the broad ligament: a case report and review of the literature".PMID 15104307
  166. H O Goyal et al. (2004). "Abnormal morphology of the penis in male rats exposed neonatally to diethylstilbestrol is associated with altered profile of estrogen receptor-alpha protein, but not of androgen receptor protein: a developmental and immunocytochemical study".PMID 14749301
  167. R Halperin et al. (2003). "Simultaneous carcinoma of the endometrium and ovary vs endometrial carcinoma with ovarian metastases: a clinical and immunohistochemical determination".PMID 12631217
  168. M Herbert et al. (2002). "Breast hamartomas: clinicopathological and immunohistochemical studies of 24 cases".PMID 12121234
  169. R Halperin et al. (2001). "Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma".PMID 11603217
  170. W Park et al. (1996). "Identification of a variant estrogen receptor lacking exon 4 and its coexpression with wild-type estrogen receptor in ovarian carcinomas".PMID 9816163